CELL DISCOV 润色咨询

Cell Discovery

出版年份：暂无数据 年文章数：199 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：0.7% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-04-25 dgdgdgygygyg

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。

    8

    展开8条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2018-09-03 ms4591412325009157

    这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差

    6

    展开6条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-11-03 ms5000001380422750

    投稿11天，不知道送审没

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-05-24 ms7000000308199462

    请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-05-14 ms4000000787672752

    审稿速度:3.0
    经验分享：underconsideration 已经两个月了

    8

    展开8条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-08-15 ms6000001231997656

    到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-07-08 ms4000000787672752

    可以有几位共一？

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-07-25 ms6000001231997656

    Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2021-11-18 121f392fm08(暂无昵称)

    第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。

    9

    展开9条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1214085, encodeId=f342121408525, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：看了一下大家对于CR和CD两本国产强刊的意见，感觉很不友好。这两本杂志势必会成为国产生物医学领域期刊的旗舰，可能以后评论区的大家可能没几个人能发的上去了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=259, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Mon Apr 25 12:47:56 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=846934, encodeId=05498469347a, content=这个杂志b格还不小啊，投过去直接拒稿，不过后来被6分的老牌杂志接受了。不看好这个杂志，给人印象很差 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Mon Sep 03 19:52:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098183, encodeId=1437209818337, content=投稿11天，不知道送审没, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39098395360, createdName=ms5000001380422750, createdTime=Thu Nov 03 10:03:01 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222074, encodeId=582e12220e4a4, content=请问大家，像类似的这种期刊，每期三篇研究论文，其余的要么综述，要么就是莱特儿，能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=180, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e5b5549664, createdName=ms7000000308199462, createdTime=Tue May 24 13:20:09 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1219617, encodeId=4642121961e65, content=审稿速度:3.0<br>经验分享：underconsideration 已经两个月了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Sat May 14 18:08:52 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238915, encodeId=d99d1238915d6, content=到8月18号就1个月了，请问投过的同志们，你们在Manuscript Under Consideration这个状态要持续多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Aug 15 23:21:49 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231253, encodeId=678c123125394, content=可以有几位共一？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cacb8111229, createdName=ms4000000787672752, createdTime=Fri Jul 08 06:55:43 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1234651, encodeId=35ff12346513e, content=Manuscript Under Consideration已经7填了，没有收到消息，投的Letter，按道理说应该很快的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fad8249532, createdName=ms6000001231997656, createdTime=Mon Jul 25 17:48:03 CST 2022, time=2022-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071385, encodeId=bab910e13855e, content=第一天投稿，第二天分配编辑，第三天就under consideration，然后两周没动静，谁知到这是审还是没审啊。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e42294781, createdName=121f392fm08(暂无昵称), createdTime=Thu Nov 18 12:32:02 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229146, encodeId=bbf61229146ea, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：新的IF出来了，38.079分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/18/56186736f4d1be1601744995196f2ab0.jpg, createdBy=a3d41955761, createdName=dgdgdgygygyg, createdTime=Tue Jun 28 13:58:54 CST 2022, time=2022-06-28, status=1, ipAttribution=)]
    2022-06-28 dgdgdgygygyg

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：新的IF出来了，38.079分。

    3

    展开3条回复
共150条页码: 2/15页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分